27934808|t|Presence of metallo-beta-lactamases (MBL), extended-spectrum beta-lactamase (ESBL) & AmpC positive non-fermenting Gram-negative bacilli among Intensive Care Unit patients with special reference to molecular detection of blaCTX-M & blaAmpC genes
27934808|a|Non-fermenting Gram-negative bacilli (NFGNB) including Pseudomonas aeruginosa and Acinetobacter baumannii have been implicated in a variety of infections, particularly in the Intensive Care Units (ICUs). This study was aimed to overview the burden of multidrug-resistant NFGNB causing infections in ICU and also to assess the occurrence of extended-spectrum beta-lactamases (ESBLs), AmpC and metallo-beta-lactamases (MBLs) among these isolates. Bacterial culture, identification and antibiotic susceptibility were carried out. ESBL s and AmpC were detected both phenotypically and genotypically. MBL was detected by modified Hodge and imipenem-ethylenediaminetetraacetic acid double-disc synergy test. NFGNB represented 45 (37%) of total 121 Gram negative isolates. Multidrug resistance was observed in 66.9 per cent and 72.5 per cent isolates of P. aeruginosa and A. baumannii, respectively. Detection by phenotypic methods showed presence of ESBL, AmpC and MBL in 21.4, 51.1 and 21.4 per cent isolates, respectively. When detected genotypically by polymerase chain reaction, ESBL and AmpC were detected in 21.4 and 41.4 per cent of NFGNB isolates, respectively. BlaCTX-M (21.4%) was the most prevalent gene responsible for ESBL production. Most of the NFGNB isolated from ICU patients were multidrug-resistant and producers of ESBL, AmpC and MBL. A regular surveillance is required to detect ESBL, AmpC and MBL producers, especially in ICU patients.
27934808	0	8	Presence	T033	C0150312
27934808	12	35	metallo-beta-lactamases	T116,T126	C0597979
27934808	37	40	MBL	T116,T126	C0597979
27934808	43	75	extended-spectrum beta-lactamase	T116,T126	C0486433
27934808	77	81	ESBL	T116,T126	C0486433
27934808	85	89	AmpC	T116,T126	C0164503
27934808	90	98	positive	T033	C1446409
27934808	99	135	non-fermenting Gram-negative bacilli	T007	C0445801
27934808	142	161	Intensive Care Unit	T073,T093	C0021708
27934808	162	170	patients	T101	C0030705
27934808	197	216	molecular detection	T059	C0022885
27934808	220	228	blaCTX-M	T028	C0017337
27934808	231	244	blaAmpC genes	T028	C0017337
27934808	245	281	Non-fermenting Gram-negative bacilli	T007	C0445801
27934808	283	288	NFGNB	T007	C0445801
27934808	300	322	Pseudomonas aeruginosa	T007	C0033809
27934808	327	350	Acinetobacter baumannii	T007	C0314787
27934808	388	398	infections	T046	C3714514
27934808	420	440	Intensive Care Units	T073,T093	C0021708
27934808	442	446	ICUs	T073,T093	C0021708
27934808	454	459	study	T062	C2603343
27934808	473	481	overview	T170	C0814812
27934808	496	515	multidrug-resistant	T032	C0242640
27934808	516	521	NFGNB	T007	C0445801
27934808	530	540	infections	T046	C3714514
27934808	544	547	ICU	T073,T093	C0021708
27934808	585	618	extended-spectrum beta-lactamases	T116,T126	C0486433
27934808	620	625	ESBLs	T116,T126	C0486433
27934808	628	632	AmpC	T116,T126	C0164503
27934808	637	660	metallo-beta-lactamases	T116,T126	C0597979
27934808	662	666	MBLs	T116,T126	C0597979
27934808	680	688	isolates	T007	C0004611
27934808	690	707	Bacterial culture	T059	C0430402
27934808	728	753	antibiotic susceptibility	T033	C0427965
27934808	772	776	ESBL	T116,T126	C0486433
27934808	783	787	AmpC	T116,T126	C0164503
27934808	793	801	detected	T033	C0442726
27934808	807	821	phenotypically	T059	C1285572
27934808	826	839	genotypically	T059	C1285573
27934808	841	844	MBL	T116,T126	C0597979
27934808	849	857	detected	T033	C0442726
27934808	870	945	Hodge and imipenem-ethylenediaminetetraacetic acid double-disc synergy test	T059	C0427971
27934808	947	952	NFGNB	T007	C0445801
27934808	987	1009	Gram negative isolates	T007	C0018150
27934808	1011	1031	Multidrug resistance	T032	C0242640
27934808	1080	1088	isolates	T007	C0004611
27934808	1092	1105	P. aeruginosa	T007	C0033809
27934808	1110	1122	A. baumannii	T007	C0314787
27934808	1138	1147	Detection	T033	C0442726
27934808	1151	1169	phenotypic methods	T059	C1285572
27934808	1189	1193	ESBL	T116,T126	C0486433
27934808	1195	1199	AmpC	T116,T126	C0164503
27934808	1204	1207	MBL	T116,T126	C0597979
27934808	1240	1248	isolates	T007	C0004611
27934808	1269	1277	detected	T033	C0442726
27934808	1278	1291	genotypically	T059	C1285573
27934808	1295	1320	polymerase chain reaction	T063	C0032520
27934808	1322	1326	ESBL	T116,T126	C0486433
27934808	1331	1335	AmpC	T116,T126	C0164503
27934808	1341	1349	detected	T033	C0442726
27934808	1379	1384	NFGNB	T007	C0445801
27934808	1385	1393	isolates	T007	C0004611
27934808	1409	1417	BlaCTX-M	T028	C0017337
27934808	1449	1453	gene	T028	C0017337
27934808	1470	1474	ESBL	T116,T126	C0486433
27934808	1475	1485	production	T038	C0220781
27934808	1499	1504	NFGNB	T007	C0445801
27934808	1519	1522	ICU	T073,T093	C0021708
27934808	1523	1531	patients	T101	C0030705
27934808	1537	1556	multidrug-resistant	T032	C0242640
27934808	1561	1570	producers	T007	C0004611
27934808	1574	1578	ESBL	T116,T126	C0486433
27934808	1580	1584	AmpC	T116,T126	C0164503
27934808	1589	1592	MBL	T116,T126	C0597979
27934808	1596	1603	regular	T080	C0205272
27934808	1604	1616	surveillance	T061	C0419786
27934808	1639	1643	ESBL	T116,T126	C0486433
27934808	1645	1649	AmpC	T116,T126	C0164503
27934808	1654	1657	MBL	T116,T126	C0597979
27934808	1658	1667	producers	T007	C0004611
27934808	1683	1686	ICU	T073,T093	C0021708
27934808	1687	1695	patients	T101	C0030705